GLP-1 Medications Are Reshaping Retail and Restaurant Site Selection

A drug originally approved for Type 2 diabetes is now showing up in retail leasing data, foot traffic counts, and site selection models. GLP-1 medications, semaglutide and tirzepatide, sold under brand names including Ozempic, Wegovy, Mounjaro and Zepbound, have moved from a niche pharmaceutical story to a measurable force in consumer spending in the span of about 18 months. Adoption estimates vary by survey methodology, but the direction is consistent, and the pace is fast: One widely cited measure found usage more than doubling, from under 6% of U.S. adults in early 2024 to over 12% by 2025, with other 2026 surveys placing current adoption meaningfully higher still.

For an industry that plans site selection and lease terms years in advance, a structural shift in appetite and spending moving this quickly is worth taking seriously, not as a curiosity, but as a real input into how trade areas and tenant categories get evaluated.

What's Actually Changing in Consumer Spending

The clearest data on the spending effect comes from Cornell University research tracking food spending before and after GLP-1 adoption. Restaurant spending fell by an average of 8% within the first six months of starting the medication, and grocery trip spending dropped by 5% to 8% over the same window, according to the study. Both effects moderate somewhat after patients discontinue use, though a meaningful share of users stay on the medications well beyond the first year.

That's a modest per-person effect, but it compounds at scale. Different 2026 surveys put current U.S. adoption anywhere from roughly one in eight adults to closer to one in five households with at least one current user, depending on how the survey is structured and who's counted. Even at the more conservative end of that range, a spending reduction applied across that many households is large enough to show up in category-level sales data, and it has: Packaged food and snack categories have faced real pressure. Grocery chains, meanwhile, have begun launching dedicated GLP-1-friendly product lines built around smaller, nutrient-dense portions with higher protein and fiber content, a direct response to a customer base that's eating less per occasion but still shopping.

None of this means GLP-1 users are spending less overall. Several analyses note that this population tends to over-index on food and beverage spending generally, both before and after starting treatment, which is part of why retailers and manufacturers are responding with new products rather than writing off the segment. The shift is in composition and quantity, not necessarily total spend, and that distinction matters for how a retail location's demand profile should be modeled going forward.

This isn't purely a U.S. story, though the U.S. remains the most advanced market for both adoption and available data. A January 2026 survey by the UK's Food Foundation found 7% of the British population had already used a GLP-1 medication, with another 8% considering it, and UK supermarkets have started rolling out their own portion-controlled, GLP-1-oriented product lines in response. For companies with international retail footprints, this is a trend to model market by market rather than to assume adoption applies uniformly.

The Adoption Pattern Isn't Uniform

Who is adopting GLP-1 medications, and why, varies in ways that matter for site selection specifically. Industry research distinguishes between two overlapping populations: Users managing diabetes or another disease state, who tend to come from larger households across a broader income range, and users pursuing weight loss primarily, who tend to skew more affluent. That second group has grown fast. One industry analysis found the share of GLP-1 users citing weight loss as their primary reason for taking the medication rose from roughly 37% in 2021 to 78% more recently, a meaningful shift in who's driving demand.

That distinction matters because adoption isn't evenly distributed across trade areas. A market with a higher concentration of affluent, health-conscious households is likely seeing faster GLP-1 adoption, and a correspondingly faster shift in category-level spending, than a market where adoption is concentrated among disease management rather than discretionary weight loss. A retail or restaurant concept evaluating two demographically different trade areas shouldn't assume this trend is affecting both at the same pace.

What This Means for Site Selection Right Now

The practical implication is that demand models built on historical trade-area performance data may already be miscalibrated for certain tenant categories, particularly quick-service restaurants, packaged snack retail, and casual dining concepts with per-visit spending or volume assumptions baked in from pre-2024 data. A site's projected performance for one of these categories, modeled on three or five years of trailing sales history, is modeling a customer base that's changing underneath it.

The corresponding opportunity sits on the other side of the same shift. Fitness, wellness, and fresh-format grocery or prepared-food concepts are showing traffic and leasing strength that looks structural rather than seasonal, which makes them worth weighting more heavily as anchors and co-tenants when evaluating a center's overall tenant mix, not just as individual site opportunities.

A newer category is also emerging worth tracking even if it's not yet mainstream in retail site selection: specialty pharmacy, medical weight-management clinics, and telehealth-linked retail formats are starting to compete for the kind of accessible, high-visibility space that was once purely retail territory, blurring the line between retail and medical site selection criteria for companies evaluating both.

A Practical Approach for Site Selection

A few adjustments are worth making to how this gets factored into site selection work:

• Re-examine demand models for any tenant category where reduced appetite or smaller per-visit spending plausibly affects unit economics, rather than assuming historical trailing data already captures the shift.
• Weight fitness, wellness, and fresh-format tenants more heavily when evaluating a center's overall anchor and co-tenant mix, given the traffic and leasing data behind the category.
• Track specialty pharmacy and weight-management retail formats as an emerging category worth monitoring, even for teams that don't currently work across both retail and medical real estate.
• Treat current adoption figures as a moving target. Usage has roughly doubled within about 18 months by some measures, and a site selection assumption locked in even a year ago may already be dated.

Building Current Behavior into the Model, Not Just Historical Sales

This kind of shift is exactly why you need to use current consumer behavior data for retail site selection work rather than relying solely on trailing sales history or static demographic profiles. A trade area that looked strong for a given tenant category three years ago isn't automatically still strong today, and the firms that catch structural shifts like this one early are the ones that avoid recommending sites, or renewing leases, based on a customer base that's already changed.

If your retail or restaurant portfolio includes concepts that could be exposed to this shift—quick-service, packaged snack-adjacent, or high-volume casual dining formats in particular—it's worth having your trade area assumptions reviewed against current behavior data rather than trailing averages alone.